Prostate cancer (PC) ranks as the second leading cause of cancer-related deaths among American men, claiming over 34,700 lives annually 1. While androgen deprivation therapy (ADT) is initially ...
Early diagnosis of prostate cancer (PCa) is crucial, but the widely used prostate-specific antigen (PSA) biomarker lacks specificity in the 4.0–10.0 ng/mL grey zone, causing many unnecessary biopsies.
The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...
Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...
Role of 18F-flotufolastat PET/CT imaging in men with high-risk prostate cancer following conventional imaging and associated changes in medical management: A phase 3b investigator-initiated trial.
Potential risk factors, course of disease, and clinical outcomes of neuroendocrine prostate cancer (NEPC): A retrospective analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results